Institute of Medical Virology, Hospital of the Johann Wolfgang Goethe University of Frankfurt, Frankfurt, Germany.
Med Microbiol Immunol. 2010 Feb;199(1):53-60. doi: 10.1007/s00430-009-0136-3. Epub 2009 Dec 1.
Since the dynamics of transmission of human cytomegalovirus (HCMV) have not been clarified yet, we assessed a possible change in HCMV seroprevalence in Frankfurt am Main, Germany during the past twenty years and tried to detect variables with an impact on epidemiology. Between 1/1/1988 and 10/15/2008, a total of 54443 serum samples were collected for routine diagnostics and analyzed using Enzygnost Anti HCMV-IgG enzyme immunoassay (Siemens/Dade Behring, Marburg, Germany). Two decades, 1/1/1988-12/31/1997 and 1/1/1998-10/15/2008, and several groups (type of health insurance, gender, age, HIV-status) were evaluated to assess changes in seroprevalence. Regarding both decades, the overall age-adjusted prevalence of HIV-negative patients dropped from 63.70% (confidence interval (CI) 95% 63.15-64.25) to 57.25% (CI 95% 56.57-57.93; P < 0.0001). Private health insurance (PHI) patients showed significant lower HCMV seroprevalences than members of obligatory health insurances (OHI) in both decades (1988-1997: PHI = 55.79%, OHI = 64.27%; P < 0.0001; 1998-1908: PHI = 47.02%, OHI = 58.74%; P < 0.0001). Furthermore, comparing the two decades, there was generally a gender-specific statistically significant decrease in HCMV seroprevalence for males (63.54-55.54%) and females (63.83-58.73%) as well as for members of PHI and OHI (PHI males: 57.59% to 47.19%, PHI females 54.10-46.80%; OHI males: 64.00-57.06%, OHI females 64.50-60.11%). Also, while female HIV-positive patients showed significant difference in HCMV seroprevalence between the two decades (83.17 and 87.80%, P = 0.023), there was no significant difference in male patients with HIV (88.76 and 87.32% in the first and second decade, respectively (P = 0.196). The cumulative HCMV prevalence of all HIV-negative patients tested in the past 20 years demonstrates a biphasic, age-related rise of HCMV seroprevalence throughout all age-groups. The seroprevalence of HCMV has declined between 1988-1997 and 1998-2008 in Frankfurt am Main, Germany. The decline varied between different age-groups. HCMV prevalence correlates with the type of health insurance, gender, age, and HIV-status.
由于人类巨细胞病毒(HCMV)的传播动力学尚未阐明,我们评估了过去 20 年在德国美因河畔法兰克福 HCMV 血清阳性率的可能变化,并试图检测对流行病学有影响的变量。在 1988 年 1 月 1 日至 2008 年 10 月 15 日期间,共采集了 54443 份血清样本用于常规诊断,并使用 Enzygnost Anti HCMV-IgG 酶免疫分析(Siemens/Dade Behring,马尔堡,德国)进行分析。过去 20 年(1988 年 1 月 1 日至 1997 年 12 月 31 日和 1998 年 1 月 1 日至 2008 年 10 月 15 日),评估了两组(健康保险类型、性别、年龄、HIV 状况)以评估血清阳性率的变化。对于这两个十年,调整年龄后的 HIV 阴性患者的总体阳性率从 63.70%(95%置信区间[CI]95%63.15-64.25)下降到 57.25%(95%CI95%56.57-57.93;P<0.0001)。在这两个十年中,私人健康保险(PHI)患者的 HCMV 阳性率明显低于强制性健康保险(OHI)患者(1988-1997 年:PHI=55.79%,OHI=64.27%;P<0.0001;1998-1998 年:PHI=47.02%,OHI=58.74%;P<0.0001)。此外,与两个十年相比,男性(63.54-55.54%)和女性(63.83-58.73%)以及 PHI 和 OHI 成员(PHI 男性:57.59%-47.19%,PHI 女性 54.10-46.80%;OHI 男性:64.00%-57.06%,OHI 女性 64.50-60.11%)的 HCMV 阳性率均呈性别特异性统计学显著下降。此外,虽然女性 HIV 阳性患者在两个十年间的 HCMV 阳性率存在显著差异(分别为 83.17%和 87.80%,P=0.023),但男性 HIV 阳性患者中没有明显差异(分别为 88.76%和 87.32%,分别为第一和第二个十年,P=0.196)。过去 20 年中所有 HIV 阴性患者的累积 HCMV 阳性率显示出与年龄相关的双相上升趋势,所有年龄组的 HCMV 血清阳性率均呈上升趋势。在德国美因河畔法兰克福,1988-1997 年至 1998-2008 年间,HCMV 的血清阳性率下降。下降幅度因年龄组而异。HCMV 流行率与健康保险类型、性别、年龄和 HIV 状况相关。